MX2023006284A - Composicion farmaceutica de agonistas duales de glp-1/glp-2. - Google Patents

Composicion farmaceutica de agonistas duales de glp-1/glp-2.

Info

Publication number
MX2023006284A
MX2023006284A MX2023006284A MX2023006284A MX2023006284A MX 2023006284 A MX2023006284 A MX 2023006284A MX 2023006284 A MX2023006284 A MX 2023006284A MX 2023006284 A MX2023006284 A MX 2023006284A MX 2023006284 A MX2023006284 A MX 2023006284A
Authority
MX
Mexico
Prior art keywords
glp
pharmaceutical composition
dual agonists
agonists
dual
Prior art date
Application number
MX2023006284A
Other languages
English (en)
Inventor
Lise Giehm
Jesper Skodborg VILLADSEN
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2023006284A publication Critical patent/MX2023006284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que comprenden conservantes particulares.
MX2023006284A 2020-12-16 2021-12-16 Composicion farmaceutica de agonistas duales de glp-1/glp-2. MX2023006284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20214562 2020-12-16
PCT/EP2021/086147 WO2022129311A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (1)

Publication Number Publication Date
MX2023006284A true MX2023006284A (es) 2023-06-13

Family

ID=74141274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006284A MX2023006284A (es) 2020-12-16 2021-12-16 Composicion farmaceutica de agonistas duales de glp-1/glp-2.

Country Status (12)

Country Link
US (1) US20240024425A1 (es)
EP (1) EP4262745A1 (es)
JP (1) JP2023553561A (es)
KR (1) KR20230121823A (es)
CN (1) CN116710114A (es)
AU (1) AU2021404497A1 (es)
CA (1) CA3200526A1 (es)
CL (1) CL2023001747A1 (es)
IL (1) IL301893A (es)
MX (1) MX2023006284A (es)
TW (1) TW202228764A (es)
WO (1) WO2022129311A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3228429A1 (en) * 2021-09-03 2023-03-09 Mikkel Askjar Agersnap Dosage regime

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
ATE525083T1 (de) * 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists

Also Published As

Publication number Publication date
KR20230121823A (ko) 2023-08-21
US20240024425A1 (en) 2024-01-25
EP4262745A1 (en) 2023-10-25
AU2021404497A1 (en) 2023-06-08
CL2023001747A1 (es) 2024-01-19
IL301893A (en) 2023-06-01
WO2022129311A1 (en) 2022-06-23
CA3200526A1 (en) 2022-06-23
JP2023553561A (ja) 2023-12-22
TW202228764A (zh) 2022-08-01
CN116710114A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2020013853A (es) Compuestos innovadores.
MX2019004611A (es) Metodos y composiciones para cambiar la composicion del microbioma de la piel usando mezclas complejas de cepas bacterianas.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2018012087A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
UY31261A1 (es) Imidazopiridinonas, composiciones que las contienen, procedimientos para su preparacion, intermedios utilizados en tales procedimientos y aplicaciones.
ZA202107825B (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
CR11398A (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo.
MX2022001719A (es) Formulaciones de conjugados de benzazepina y usos de las mismas.
MX2022013768A (es) Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
MX2020008125A (es) Composiciones que comprenden berberina.
SA519402556B1 (ar) تركيبات تجميلية للعناية بالبشرة.
MX2023006280A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2023006284A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
MX2019009235A (es) Compuestos antifibroticos.
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
EA202090788A1 (ru) Жидкая композиция для использования в качестве противовоспалительного средства
MX2019014192A (es) Inhibidor de inmunosupresion asociado al cancer.
MX2023000557A (es) Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas.